FindTrial
Sign In

Enavogliflozin

DRUG7 trials

Sponsors

Duk-Woo Park, MD, Daewoong Pharmaceutical Co. LTD., Asan Medical Center, Seoul National University Bundang Hospital, Yonsei University

Conditions

Aortic Valve StenosisAtrial FibrillationCardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureHeart Failure With Preserved Ejection FractionKidney DiseasesObesity and Type 2 Diabetes

Phase 3

Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Active, not recruitingNCT06027307
Asan Medical CenterHeart Failure With Preserved Ejection Fraction, Tricuspid Regurgitation
Start: 2023-10-25End: 2027-08-31Updated: 2025-12-29

Phase 4

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
RecruitingNCT05672836
Duk-Woo Park, MDAortic Valve Stenosis, Heart Failure
Start: 2024-12-18End: 2029-04-01Target: 1040Updated: 2026-06-29
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
RecruitingNCT06399835
Seoul National University Bundang HospitalType 2 Diabetes
Start: 2024-02-01End: 2027-12-31Target: 120Updated: 2026-05-05
Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation
RecruitingNCT06528262
Yonsei UniversityAtrial Fibrillation
Start: 2025-04-03End: 2027-05-31Target: 390Updated: 2026-05-12
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
RecruitingNCT06642623
Yonsei UniversityCardiovascular Diseases, Diabetes Mellitus, Type 2, Kidney Diseases
Start: 2024-01-22End: 2030-12-31Target: 2862Updated: 2024-10-15
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
RecruitingNCT06782139
Korea University Anam HospitalObesity and Type 2 Diabetes
Start: 2025-01-20End: 2025-12-31Target: 30Updated: 2025-09-02

Unknown Phase

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
Active, not recruitingNCT05926414
Daewoong Pharmaceutical Co. LTD.Diabetes Mellitus, Type 2
Start: 2023-09-21End: 2025-12-31Target: 15000Updated: 2025-09-02